Free Trial
NASDAQ:MNPR

Monopar Therapeutics (MNPR) Stock Price, News & Analysis

Monopar Therapeutics logo
$25.79 -0.03 (-0.12%)
(As of 11:16 AM ET)

About Monopar Therapeutics Stock (NASDAQ:MNPR)

Key Stats

Today's Range
$25.31
$27.11
50-Day Range
$4.63
$32.66
52-Week Range
$1.54
$38.50
Volume
10,278 shs
Average Volume
625,090 shs
Market Capitalization
$136.12 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$27.33
Consensus Rating
Buy

Company Overview

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

Monopar Therapeutics Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
40th Percentile Overall Score

MNPR MarketRank™: 

Monopar Therapeutics scored higher than 40% of companies evaluated by MarketBeat, and ranked 697th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Monopar Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Monopar Therapeutics has only been the subject of 2 research reports in the past 90 days.

  • Read more about Monopar Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Monopar Therapeutics are expected to grow in the coming year, from ($1.65) to ($1.48) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Monopar Therapeutics is -13.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Monopar Therapeutics is -13.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Monopar Therapeutics has a P/B Ratio of 13.73. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    0.70% of the float of Monopar Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Monopar Therapeutics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Monopar Therapeutics has recently decreased by 18.22%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Monopar Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Monopar Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.70% of the float of Monopar Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Monopar Therapeutics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Monopar Therapeutics has recently decreased by 18.22%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Monopar Therapeutics has a news sentiment score of 0.85. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Monopar Therapeutics this week, compared to 2 articles on an average week.
  • Search Interest

    Only 5 people have searched for MNPR on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.
  • MarketBeat Follows

    Only 3 people have added Monopar Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -57% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Monopar Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $25,188.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    34.90% of the stock of Monopar Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 1.83% of the stock of Monopar Therapeutics is held by institutions.

  • Read more about Monopar Therapeutics' insider trading history.
Receive MNPR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Monopar Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MNPR Stock News Headlines

Close up view of the smartphone on neon keyboard with sezzle logo — Stock Editorial Photography
3 Momentum Stocks Soaring Into 2025 and Beyond (MNPR)
Given the S&P's strong performance in the last year, momentum stock plays are those that have exceeded that high bar; here are three companies with potential.
Monopar Therapeutics prices 798,655 shares at $23.79 in registered offering
$2 Trillion Disappears Because of Fed's Secretive New Move
$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being carried out by the Fed that has nothing to do with lowering or raising interest rates... but could soon have an enormous impact on your wealth.
See More Headlines

MNPR Stock Analysis - Frequently Asked Questions

Monopar Therapeutics' stock was trading at $1.7010 on January 1st, 2024. Since then, MNPR stock has increased by 1,417.9% and is now trading at $25.82.
View the best growth stocks for 2024 here
.

Monopar Therapeutics Inc. (NASDAQ:MNPR) posted its earnings results on Friday, November, 8th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.46) by $0.09.

Monopar Therapeutics's stock reverse split before market open on Tuesday, August 13th 2024. The 1-5 reverse split was announced on Friday, August 9th 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 12th 2024. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.

Monopar Therapeutics subsidiaries include these companies: Monopar Therapeutics Pty Ltd, and Monopar Therapeutics SARL.

Monopar Therapeutics (MNPR) raised $9 million in an IPO on Thursday, December 19th 2019. The company issued 1,100,000 shares at $8.00 per share. JonesTrading served as the underwriter for the IPO and Arcadia Securities was co-manager.

Shares of MNPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Monopar Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Avino Silver & Gold Mines (ASM), Avino Silver & Gold Mines (ASM), GlycoMimetics (GLYC), Barrick Gold (GOLD) and Tonix Pharmaceuticals (TNXP).

Company Calendar

Last Earnings
11/08/2024
Today
12/22/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:MNPR
Fax
N/A
Employees
10
Year Founded
2014

Price Target and Rating

Average Stock Price Target
$27.33
High Stock Price Target
$50.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+5.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-8,400,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.88 per share

Miscellaneous

Free Float
3,436,000
Market Cap
$136.28 million
Optionable
Not Optionable
Beta
1.23

Social Links

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

This page (NASDAQ:MNPR) was last updated on 12/23/2024 by MarketBeat.com Staff
From Our Partners